US 12,084,515 B2
Compositions and methods for treatment of diabetic macular edema
Gregory P. Conley, Arlington, MA (US); Andrew Nixon, Hanover, MA (US); and Daniel J. Sexton, Melrose, MA (US)
Assigned to Takeda Pharmaceutical Company Limited, Osaka (JP)
Filed by Takeda Pharmaceutical Company Limited, Osaka (JP)
Filed on Jun. 11, 2021, as Appl. No. 17/345,033.
Application 17/345,033 is a continuation of application No. 16/541,743, filed on Aug. 15, 2019, granted, now 11,046,785.
Application 16/541,743 is a continuation of application No. 14/669,607, filed on Mar. 26, 2015, granted, now 10,428,158.
Claims priority of provisional application 61/971,170, filed on Mar. 27, 2014.
Prior Publication US 2022/0033521 A1, Feb. 3, 2022
Int. Cl. A61K 39/00 (2006.01); A61P 27/02 (2006.01); C07K 16/40 (2006.01); A61K 9/00 (2006.01)
CPC C07K 16/40 (2013.01) [A61P 27/02 (2018.01); A61K 9/0051 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); C07K 2317/30 (2013.01); C07K 2317/55 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 10 Claims
 
1. A method for treating a retinal disease in a subject, the method comprising:
administering an effective amount of a composition comprising an antibody that binds to active human plasma kallikrein to a subject in need thereof, wherein the antibody comprises:
(i) a heavy chain variable region comprising a complementarity determining region (CDR) 1 set forth as HYIMM (SEQ ID NO: 5), a CDR2 set forth as GIYSSGGITVYADSVKG (SEQ ID NO: 6), and a CDR3 set forth as QRTGVPRRDSFNI (SEQ ID NO: 44), a light chain variable region comprising a CDR1 set forth as RASQSISSWLA (SEQ ID NO: 8), a CDR2 set forth as KASTLES (SEQ ID NO: 9), and a CDR3 set forth as QQYNTYWT (SEQ ID NO: 10);
(ii) a heavy chain variable region comprising a CDR1 set forth as HYIMM (SEQ ID NO: 5), a CDR2 set forth as GIYSSGGITVYADSVKG (SEQ ID NO: 6), and a CDR3 set forth as RRTGVPRRDEFDI (SEQ ID NO: 46), a light chain variable region comprising a CDR1 set forth as RASQSISSWLA (SEQ ID NO: 8), a CDR2 set forth as KASTLES (SEQ ID NO: 9), and a CDR3 set forth as QQYNTYWT (SEQ ID NO: 10);
(iii) a heavy chain variable region comprising a CDR1 set forth as HYIMM (SEQ ID NO: 5), a CDR2 set forth as GIYSSGGITVYADSVKG (SEQ ID NO: 6), and a CDR3 set forth as RRIGVPRRDSFDM (SEQ ID NO: 52), a light chain variable region comprising a CDR1 set forth as RASQSISSWLA (SEQ ID NO: 8), a CDR2 set forth as KASTLES (SEQ ID NO: 9), and a CDR3 set forth as QQYNTYWT (SEQ ID NO: 10); or
(iv) a heavy chain variable region comprising a CDR1 set forth as HYIMM (SEQ ID NO: 5), a CDR2 set forth as GIYSSGGITVYADSVKG (SEQ ID NO: 6), and a CDR3 set forth as RRIGVPRRDDFDI (SEQ ID NO: 53), a light chain variable region comprising a CDR1 set forth as RASQSISSWLA (SEQ ID NO: 8), a CDR2 set forth as KASTLES (SEQ ID NO: 9), and a CDR3 set forth as QQYNTYWT (SEQ ID NO: 10); and
wherein the retinal disease is selected from the group consisting of diabetic macular edema (DME), age-related macular degeneration (AMD), and retinal vein occlusion (RVO).